{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:38:46Z","timestamp":1792640326514,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cll.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T08:58:01Z","timestamp":1625129881000},"page":"325-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hematopathologic Correlates of CAR T-Cell Therapy"],"prefix":"10.1016","volume":"41","author":[{"given":"J. Gregory","family":"Dolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele E.","family":"Paessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cll.2021.03.012_bib1","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.cll.2021.03.012_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrclinonc.2017.176","article-title":"Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm","volume":"15","author":"Teachey","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.cll.2021.03.012_bib3","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T\u00a0cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"issue":"6382","key":"10.1016\/j.cll.2021.03.012_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T\u00a0cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.cll.2021.03.012_bib6","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.cll.2021.03.012_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9967","key":"10.1016\/j.cll.2021.03.012_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.cll.2021.03.012_bib9","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T\u00a0cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.cll.2021.03.012_bib11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2021.03.012_bib12","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T\u00a0cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.cll.2021.03.012_bib15","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cll.2021.03.012_bib16","doi-asserted-by":"crossref","first-page":"e27265","DOI":"10.1002\/pbc.27265","article-title":"Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia","volume":"65","author":"Oberley","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.cll.2021.03.012_bib17","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","article-title":"Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children","volume":"34","author":"Pan","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.cll.2021.03.012_bib18","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ajh.25775","article-title":"Loss of surface CD3 expression in allogeneic CAR T-cells","volume":"95","author":"Margolskee","year":"2020","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.cll.2021.03.012_bib19","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2007-05-090340","article-title":"Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.cll.2021.03.012_bib20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cll.2021.03.012_bib21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.cll.2021.03.012_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T\u00a0cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.cll.2021.03.012_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.cll.2021.03.012_bib24","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cll.2021.03.012_bib25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cyto.b.21891","article-title":"Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: benefits and challenges","volume":"100","author":"Sarikonda","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.cll.2021.03.012_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cyto.b.21880","article-title":"New directions in chimeric antigen receptor T\u00a0cell [CAR-T] therapy and related flow cytometry","volume":"98","author":"Maryamchik","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"15","key":"10.1016\/j.cll.2021.03.012_bib28","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cll.2021.03.012_bib29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.cll.2021.03.012_bib30","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2016.34.15_suppl.3007","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T\u00a0cells in children with relapsed ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.cll.2021.03.012_bib31","first-page":"1319","article-title":"Durable remissions with humanized CD19-targeted chimeric antigen receptor (CAR)-modified T\u00a0cells in CAR-naive and CAR-exposed children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"130","author":"Maude","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.cll.2021.03.012_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T\u00a0cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cll.2021.03.012_bib33","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.bbmt.2020.04.003","article-title":"Exploring the dilemma of allogeneic hematopoietic cell transplantation after chimeric antigen receptor T\u00a0cell therapy: to transplant or not?","volume":"26","author":"Bouziana","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cyto.b.21482","article-title":"A\u00a0novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia\/lymphoma post anti-CD19 therapy","volume":"94","author":"Cherian","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"Supplement 1","key":"10.1016\/j.cll.2021.03.012_bib35","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2018-99-115460","article-title":"Molecular detection of minimal residual disease precedes morphological relapse and could be used to identify relapse in pediatric and young adult B-cell acute lymphoblastic leukemia patients treated with tisagenlecleucel","volume":"132","author":"Pulsipher","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2021.03.012_bib36","doi-asserted-by":"crossref","first-page":"e28149","DOI":"10.1002\/pbc.28149","article-title":"Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: opportunities for improvement","volume":"67","author":"Shalabi","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"10.1016\/j.cll.2021.03.012_bib37","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.cll.2021.03.012_bib38","first-page":"655","article-title":"ctDNA predicts outcomes in DLBCL","volume":"15","author":"Sidaway","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.cll.2021.03.012_bib39","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T\u00a0cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.cll.2021.03.012_bib40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","article-title":"CD19-targeting CAR T\u00a0cell immunotherapy outcomes correlate with genomic modification by vector integration","volume":"130","author":"Nobles","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.cll.2021.03.012_bib41","doi-asserted-by":"crossref","first-page":"e001052","DOI":"10.1136\/jitc-2020-001052","article-title":"Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T\u00a0cells","volume":"8","author":"Willier","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"625","key":"10.1016\/j.cll.2021.03.012_bib42","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T\u00a0cell survival through noncanonical NF-kappaB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"issue":"2","key":"10.1016\/j.cll.2021.03.012_bib43","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/nar\/gky1231","article-title":"Aberrant splicing in B-cell acute lymphoblastic leukemia","volume":"47","author":"Black","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.cll.2021.03.012_bib44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.cll.2021.03.012_bib45","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.cll.2021.03.012_bib46","doi-asserted-by":"crossref","first-page":"e00383-18","DOI":"10.1128\/MCB.00383-18","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","author":"Bagashev","year":"2018","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.cll.2021.03.012_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T\u00a0cells","volume":"171","author":"Evans","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2021.03.012_bib48","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"7750","key":"10.1016\/j.cll.2021.03.012_bib49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T\u00a0cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cll.2021.03.012_bib50","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.cll.2021.03.012_bib51","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor intrinsic and extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cll.2021.03.012_bib52","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020005123","article-title":"Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.cll.2021.03.012_bib54","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T\u00a0cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cll.2021.03.012_bib55","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.cll.2021.03.012_bib56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2017-04-779009","article-title":"CART attack","volume":"130","author":"Pillai","year":"2017","journal-title":"Blood"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:58:08Z","timestamp":1759449488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271221000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0272271221000123"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2021.03.012","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopathologic Correlates of CAR T-Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}